Norwood Abbey Limited, (OTC:NABYY)(OTC:NABYF)(ASX:NAL), an immunology therapy company focused on technology to rejuvenate the immune system, announces the intention to appoint Mr. Rolf Stahel, the former Chief Executive of Shire Pharmaceuticals, as Non-Executive Chairman, on admission of the Company’s shares to the AIM Market of the London Stock Exchange. Simultaneous to this announcement, Norwood Immunology has confirmed that its Pathfinder Admission Document for its AIM flotation will be released today. Mr. Stahel, 60, has approximately 37 years’ experience in the healthcare industry, including at board level in his role as Chief Executive of Shire Pharmaceuticals Group plc (“Shire”). Prior to his role at Shire, Mr. Stahel worked for 27 years with Wellcome plc in Switzerland, Italy, Thailand, Singapore and the UK. His last position with Wellcome plc was Director of Group Marketing, responsible for group strategy, research and development evaluation, marketing of existing and new products and business development.
